The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular profiling-based prognostic prediction of patients with advanced small-cell lung cancer.
 
Hibiki Udagawa
No Relationships to Disclose
 
Shigeki Umemura
Honoraria - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst)
 
Sachiyo Mimaki
No Relationships to Disclose
 
Genichiro Ishii
No Relationships to Disclose
 
Keisuke Kirita
No Relationships to Disclose
 
Shingo Matsumoto
Honoraria - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Takeda (Inst)
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Hironobu Ohmatsu
No Relationships to Disclose
 
Katsuya Tsuchihara
No Relationships to Disclose
 
Koichi Goto
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda